Biogen Company Profile (NASDAQ:BIIB)

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, July, 25th. The company reported $5.04 EPS for the quarter, beating the Zacks' consensus estimate of $4.36 by $0.68. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The company's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business earned $5.21 earnings per share. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Biogen.

Biogen updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $20.80-21.40 for the period, compared to the Thomson Reuters consensus estimate of $20.37. The company issued revenue guidance of $11.5-11.8 billion, compared to the consensus revenue estimate of $11.40 billion.

25 analysts have issued twelve-month target prices for Biogen's shares. Their forecasts range from $271.00 to $442.00. On average, they anticipate Biogen's stock price to reach $342.83 in the next year. View Analyst Ratings for Biogen.

Here are some recent quotes from research analysts about Biogen stock:

• 1. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
• 2. Mizuho analysts commented, "We looked through early Spinraza data to draw as close to apples to apples comparison as possible. Here is a chart we found (from an old BIIB deck), which shows Spinraza increases SMN protein by ~2.7x." (10/2/2017)
• 3. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
• 4. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
• 5. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)

Some companies that are related to Biogen include Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Mirna Therapeutics (SYBX), Mereo BioPharma Group PLC (MPH), Fortress Biotech (FBIO), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), Kadmon Holdings (KDMN), Vericel Corp (VCEL) and MediWound (MDWD).

Biogen's management team includes the folowing people:

• Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board
• Michel Vounatsos, Chief Executive Officer, Director
• Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
• Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President
• Kenneth A. Di Pietro, Executive Vice President - Human Resources
• Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary
• Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development
• Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs
• Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations
• Paul McKenzie Ph.D., Executive Vice President - Pharmaceutical Operations & Technology

Biogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.22%), Assenagon Asset Management S.A. (0.19%), Rockefeller Financial Services Inc. (0.12%), Fisher Asset Management LLC (0.05%), State Treasurer State of Michigan (0.03%) and Oakbrook Investments LLC (0.03%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Biogen's stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Bridges Investment Counsel Inc., Rockefeller Financial Services Inc., Fisher Asset Management LLC, Verde Servicos Internacionais S.A., Bridges Investment Management Inc. and Mutual of America Capital Management LLC. Company insiders that have sold Biogen stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Biogen's stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Oakbrook Investments LLC, APG Asset Management N.V., Barometer Capital Management Inc., Shell Asset Management Co., Meeder Asset Management Inc., Eqis Capital Management Inc. and Montrusco Bolton Investments Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Biogen stock can currently be purchased for approximately $338.10.